期刊文献+

CAT方案治疗难治复发急性髓性白血病 被引量:1

下载PDF
导出
摘要 目的探讨CAT联合方案治疗难治或复发急性髓性白血病(AML)的疗效和不良反应。方法对42例难治或复发AML患者予CAT方案治疗,CAT方案包括环磷酰胺300~500 mg/m2,每12小时1次,第1~3天;阿糖胞昔1 000~1 500 mg/m2,1次/d,第2~6天;拓扑替康1.25 mg/m2,1次/d,第2~6天。Hb<60 g/L或出现明显贫血症状时输注浓缩红细胞。Plt<20×109.L-1或出现出血时输注血小板。中性粒细胞绝对计数<0.5×109.L-1时常规应用粒细胞集落刺激因子。结果 3例患者化疗后未复查骨髓无法评估疗效,可评估疗效39例。获得完全缓解18例(46.2%),部分缓解2例(5.1%),总有效率达51.3%,未缓解19例(48.7%)。复发时间大于12个月组的有效率明显优于复发时间小于12个月组(73.3%vs 28.6%),差异有统计学意义(P=0.027)。而难治和复发AML患者的疗效差异无统计学意义(P=1.000)。中位总生存时间16(2~88)个月,复发后中位总生存时间5(1~49)个月,12例缓解患者中位缓解时间为9(2~49)个月。骨髓抑制很普遍,非血液学毒性最常见的是感染,发生率为100%。观察期间死亡1例(2.32%)。结论 CAT方案对难治复发AML患者有较好的疗效且患者耐受性良好,值得进一步探讨。
出处 《广东医学》 CAS CSCD 北大核心 2013年第6期900-902,共3页 Guangdong Medical Journal
基金 广东省科技计划项目(编号:2011B061300033)
  • 相关文献

参考文献15

  • 1MAN C H, FUNG T K, HO C, et al. Sorafenib treatment of FLT3 -ITD( + ) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the e- mergence of a D835 mutation[J]. Blood, 2012, 119(22) : 5133 -5143.
  • 2WIERZBOWSKA A, ROBAK T, PLUTA A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G -CSF (CLAG- M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group[ J]. Eur J Haematol, 2008, 80(2) : 115 - 126.
  • 3GIL L, STYCZYNSKI J, DYTFELD D, et al. Activity of borte- zomib in adult de novo and relapsed acute myeloid leukemia[ J ]. Anticancer Res, 2007, 27(6B) : 4021 -4025.
  • 4POMMIER Y. Topoisomerase I inhibitors: camptothecins and be- yond [ J]. Nat Rev Cancer, 2006, 6 (10) : 789 -802.
  • 5KAUFMANN S H, SVINGEN P A, GORE S D, et al. Altered for- mation of topotecan - stabilized topoisomerase I - DNA adducts in human leukemia cells[J]. Blood, 1997, 89(6) : 2098 -2104.
  • 6CAROL H, HOUGHTON P J, MORTON C L, et al. Initial testing of topotecan by the pediatric preclinical testing program[J]. Pedi- atr Blood Cancer, 2010, 54(5) : 707 -715.
  • 7FURMAN W L, BAKER S D, PRATT C B, et al. Escalating sys- temic exposure of continuous infusion topotecan in children with re- current acute leukemia[J]. J Clin Oncol, 1996, 14(5) : 1504 - 1511.
  • 8HUIYA N, STEWART C F, ZHOU Y, et al. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse[J]. Cancer, 2008, 112(9) : 1983 -1991.
  • 9INABA H, STEWART C F, CREWS K R, et al. Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia[J]. Cancer, 2010, 116( 1 ) : 98 - 105.
  • 10LI X, RUAN G R, LU W L, et al. A novel stealth liposomal topo- tecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca^2+ by amlodipine thus leading to an enhanced an- titumor activity in leukemia [ J ]. J Control Release, 2006, 112 (2) : 186 - 198.

同被引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部